Navigation Links
Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment
Date:10/19/2011

This release is available in Spanish.

Researchers from Massachusetts General Hospital, Harvard Medical School and CIC bioGUNE discover a complex cell mechanism activated by a protein HOXB9 that becomes an obstacle for radiation effectiveness.

Scientists all over the world continue to focus their research on breast cancer. As a consequence, knowledge of the behaviour of tumour cells is growing, as well as of their interactions with the microenvironment. There are, however, many questions still unanswered.

A new collaborative study carried out by the laboratory of Dr Mara Vivanco, researcher at the Cell Biology and Stem Cells Unit in the Center for Cooperative Research in Biosciences, CIC bioGUNE, and the groups led by Dr Zou and Dr Maheswaran in Boston, has provided insight into one of these mysteries: a cell mechanism that explains how a protein - called HOXB9 - helps cancer cells to avoid the attack of treatments such as radiation, and prevents the therapy from having the desired effect on certain types of breast cancer.

The study was recently published in Proceedings of the National Academy of Sciences (PNAS). The study shows that cells that express higher levels of the HOXB9 transcription factor are more likely to survive the radiation used as breast cancer treatment.

A complex mechanism induced by this protein has been discovered, which manages to activate a whole chain of cell processes in which different proteins - such as ATM kinase, amongst others - intervene, and which make certain cancerous cells more resistant to treatment. Dr Vivanco explains, "when the tumour is exposed to radiation it induces DNA damage a phenomenon that results in formation of double-stranded DNA breaks - leading the cells to respond and try to repair the damage caused in the DNA using another mechanism - called the DNA damage response," by activating ATM kinase. In this way, the cell cycle is stopped and the DNA is repaired in order to maintain chromosome stability.

HOXB9 expression causes an increase in survival of cells that have been exposed to radiation. This higher resistance occurs because of the acceleration of response to radiation and its higher recovery capacity after DNA damage. On the other hand, reduction of the levels of this protein, leads to increased cell sensitivity to radiation. Furthermore, the growth factor TGFbeta (a HOXB9 target) is also involved. Therefore, HOXB9 facilitates DNA repair by activation of the TGFbeta signalling pathway, which elevates ATM phosphorylation, accelerates DNA damage response and radiation resistance.

The published research is the continuation of another study carried out last year by CIC bioGUNE, Massachusetts General Hospital and Harvard Medical School, which showed that this same protein (HOXB9) is overexpressed in breast cancer and that its expression levels are associated with high tumour grade.


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
0034-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Penn receives $12.5 million from NIH to speed discovery to patient care
2. A*STAR scientists make headway for cancer treatment and cancer prevention with landmark discovery
3. New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery
4. Sweet insight: Discovery could speed drug development
5. URMC and Temple announce drug discovery partnership
6. Stanford discovery may eliminate potentially lethal side effect of stem cell therapy
7. Brain tumor discovery could lead to new treatment
8. Discovery of a new mechanism of gene control that is associated with cancer
9. Anti-cancer drug discovery partnership formed between UMMC and Ole Miss
10. Discovery of Lung Stem Cells May Herald New Treatments
11. Discovery could change the way doctors treat patients with cancer and autoimmune diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... 2017 , ... SignatureCare Emergency Center – South Austin is treating both adult ... day. , The Emergency Room opened early March, making it the ... now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical ...
(Date:7/24/2017)... ... July 24, 2017 , ... ...      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, ... celebrate the structural topping out of the new Destination Medical Building located ...
(Date:7/24/2017)... ... ... SignatureCare Emergency Center is looking to award their 2017 Fall Scholarship. ... student. Get your applications in now as the deadline is approaching fast. ... a nursing student at Prairie View A&M University with a 3.45 GPA. Castillo was ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services has ... Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. The ... facilitate the development of a hub and spoke model for opioid treatment in ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... destroyed the construction site and threatened numerous homes and businesses nearby, causing some ... on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. notes ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology: